We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Let’s see how things are shaping up for this announcement.
Factors at Play
ACADIA is expected to benefit from the commercial launch of Nuplazid on May 31 used for the treatment of hallucinations and delusions following its FDA approval on Apr 29. The newly launched drug generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. The introduction of Nuplazid represents a major paradigm shift in the treatment of patients with PD psychosis, as it is the first and only FDA-approved treatment for hallucinations and delusions.
Meanwhile, the company is on track with its multiyear plans of developing Pimavanserin in indications beyond PD psychosis. The company has completed enrollment in a phase II exploratory study on Pimavanserin for the treatment of Alzheimer’s disease psychosis. Top-line results from this study are expected to be announced by the end of 2016.
However, Nuplazid pricing may be a cause for concern as physician, patient and payor responses are still uncertain.
Earnings Whispers
Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: ACADIA has an Earnings ESP of -1.82%. That is because the Most Accurate estimate stands at a loss of 56 cents while the Zacks Consensus Estimate pegged at a loss of 55 cents.
Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: ACADIA has a Zacks Rank #3 which increases the predictive power of ESP. However, its negative ESP makes surprise prediction difficult for the quarter.
Note that we caution against stocks with Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a few companies that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Allergan plc has an Earnings ESP of +0.56% and a Zacks Rank #3. The company is scheduled to report third-quarter results on Nov 2.
Infinity Pharmaceuticals, Inc. has an Earnings ESP of +5.81% and a Zacks Rank #1. The company is scheduled to report results on Nov 3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
ACADIA Pharma (ACAD): Will It Disappoint in Q3 Earnings?
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) is expected to report third-quarter 2016 results on Nov 3.
In the four trailing quarters, the company has missed estimates thrice, bringing the average negative earnings surprise to 15.72%.
ACADIA PHARMA Price and EPS Surprise
ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote
Let’s see how things are shaping up for this announcement.
Factors at Play
ACADIA is expected to benefit from the commercial launch of Nuplazid on May 31 used for the treatment of hallucinations and delusions following its FDA approval on Apr 29. The newly launched drug generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. The introduction of Nuplazid represents a major paradigm shift in the treatment of patients with PD psychosis, as it is the first and only FDA-approved treatment for hallucinations and delusions.
Meanwhile, the company is on track with its multiyear plans of developing Pimavanserin in indications beyond PD psychosis. The company has completed enrollment in a phase II exploratory study on Pimavanserin for the treatment of Alzheimer’s disease psychosis. Top-line results from this study are expected to be announced by the end of 2016.
However, Nuplazid pricing may be a cause for concern as physician, patient and payor responses are still uncertain.
Earnings Whispers
Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: ACADIA has an Earnings ESP of -1.82%. That is because the Most Accurate estimate stands at a loss of 56 cents while the Zacks Consensus Estimate pegged at a loss of 55 cents.
Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: ACADIA has a Zacks Rank #3 which increases the predictive power of ESP. However, its negative ESP makes surprise prediction difficult for the quarter.
Note that we caution against stocks with Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a few companies that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Ariad Pharmaceuticals Inc. is expected to report earnings on Nov 1.The company has an Earnings ESP of +5.26% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Allergan plc has an Earnings ESP of +0.56% and a Zacks Rank #3. The company is scheduled to report third-quarter results on Nov 2.
Infinity Pharmaceuticals, Inc. has an Earnings ESP of +5.81% and a Zacks Rank #1. The company is scheduled to report results on Nov 3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>